We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
-23.67%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$36.2M
AUM Growth
-$72M
(-67%)
Cap. Flow
-$56.1M
Cap. Flow
% of AUM
-155.04%
Top 10 Holdings %
Top 10 Hldgs %
74.48%
Holding
38
New
3
Increased
2
Reduced
18
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Inogen
INGN
|
+$1.66M |
| 2 |
Equillium
EQ
|
+$846K |
| 3 |
Bio-Rad Laboratories Class A
BIO
|
+$468K |
| 4 |
Insmed
INSM
|
+$208K |
| 5 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$121K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Healthcare
ACHC
|
+$6.57M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
+$3.72M |
| 3 |
DaVita
DVA
|
+$3.35M |
| 4 |
AnaptysBio
ANAB
|
+$3.31M |
| 5 |
Pfizer
PFE
|
+$3.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$22.7B
| $4.9M | 13.53% |
373,198
+13,016
| +4% | +$208K |
|
|
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $4.38M | 12.1% |
106,684
+3,235
| +3% | +$121K |
|
3
PTC Therapeutics
PTCT
$6.29B
| $3.8M | 10.5% |
110,794
-62,216
| -36% | -$2.24M |
|
|
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.32M | 9.18% |
170,129
-81,752
| -32% | -$1.68M |
|
|
AERI
5
DELISTED
Aerie Pharmaceuticals
AERI
| $2.08M | 5.73% |
57,486
-15,484
| -21% | -$726K |
|
6
Incyte
INCY
$23.7B
| $2.01M | 5.55% |
31,588
-17,832
| -36% | -$1.16M |
|
7
Centene
CNC
$31.6B
| $1.87M | 5.16% |
32,378
-17,346
| -35% | -$1.16M |
|
8
UnitedHealth
UNH
$379B
| $1.72M | 4.74% |
6,884
-8,460
| -55% | -$2.23M |
|
9
Neurocrine Biosciences
NBIX
$17.7B
| $1.47M | 4.06% |
20,571
-2,562
| -11% | -$245K |
|
10
CVS Health
CVS
$137B
| $1.42M | 3.93% |
21,739
-14,131
| -39% | -$1.05M |
|
|
11
Inogen
INGN
$171M
| $1.25M | 3.46% |
+10,072
| New | +$1.66M |
|
12
Penumbra
PEN
$12.6B
| $1.22M | 3.37% |
9,966
-3,221
| -24% | -$431K |
|
|
13
DaVita
DVA
$15.2B
| $1.09M | 3.01% |
21,156
-52,315
| -71% | -$3.35M |
|
|
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
| $932K | 2.57% |
97,294
-260,897
| -73% | -$2.87M |
|
|
XLRN
15
DELISTED
Acceleron Pharma
XLRN
| $808K | 2.23% |
18,564
-21,348
| -53% | -$1.07M |
|
16
Heron Therapeutics
HRTX
$86.9M
| $801K | 2.21% |
30,861
-24,986
| -45% | -$687K |
|
|
NCNA
17
NuCana
NCNA
$5.24M
| $624K | 1.72% |
9
-8
| -47% | -$709K |
|
|
VRAY
18
DELISTED
ViewRay, Inc.
VRAY
| $589K | 1.63% |
96,964
-126,921
| -57% | -$951K |
|
19
Verrica Pharmaceuticals
VRCA
$91.9M
| $512K | 1.41% |
6,288
-1,401
| -18% | -$170K |
|
|
20
Equillium
EQ
$156M
| $497K | 1.37% |
+60,882
| New | +$846K |
|
|
21
Bio-Rad Laboratories Class A
BIO
$8.47B
| $405K | 1.12% |
+1,745
| New | +$468K |
|
|
KDMN
22
DELISTED
Kadmon Holdings, Inc.
KDMN
| $401K | 1.11% |
192,637
-129,988
| -40% | -$327K |
|
|
DRRX
23
DELISTED
DURECT Corp
DRRX
| $111K | 0.31% |
22,882
-45,963
| -67% | -$401K |
|
|
24
Acadia Healthcare
ACHC
$2.99B
| – | – |
-186,631
| Closed | -$6.57M |
|
|
25
AnaptysBio
ANAB
$1.59B
| – | – |
-33,211
| Closed | -$3.31M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q4 2018 Portfolio in Review
As of Q4 2018, Asymmetry Capital Management held 38 positions worth $36.2M, down 67% from $108M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Asymmetry Capital Management withdrew a net $56.1M in Q4 2018, closing 15 positions and reducing 18 holdings. Its most notable exit was Acadia Healthcare, an estimated $6.57M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 86% a quarter earlier.
Against the trend, Asymmetry Capital Management opened a new position in Inogen worth $1.25M.
- Asymmetry Capital Management's largest Q4 2018 buy was Inogen: 10,072 shares worth $1.25M.
- Asymmetry Capital Management added most to Insmed in Q4 2018, an estimated $208K increase.
- Asymmetry Capital Management's biggest Q4 2018 reduction was DaVita, cutting an estimated $3.35M.
- Asymmetry Capital Management fully exited Acadia Healthcare in Q4 2018, selling an estimated $6.57M.
- Asymmetry Capital Management's ten largest holdings make up 74% of its $36.2M portfolio in Q4 2018.
- Asymmetry Capital Management opened 3 new positions and closed 15 in Q4 2018.
- Asymmetry Capital Management's portfolio value fell 67% quarter-over-quarter to $36.2M.
Based on Asymmetry Capital Management's 13F filing for Q4 2018, filed 12 Feb 2019.